Journal
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
Volume 7, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fbioe.2019.00295
Keywords
photodynamic therapy; theranostics; graphene; MXene; nanomedicine
Funding
- MIUR JTC Graphene 2015 (GIMMUNOMICS project)
- European Union's HORIZON2020 research and innovation programme under MSCA RISE2016 project Carbo-Immap [734381]
- Turkish Academy of Sciences (TUBA) under TUBA-GEBIP 2018
- McCabe Fellow Award
- University of Pennsylvania Research Foundation
Ask authors/readers for more resources
Cancer is one of the leading causes of death in the world. Therefore, the development of new advanced and targeted strategies in cancer research for early diagnosis and treatment has become essential to improve diagnosis outcomes and reduce therapy side effects. Graphene and more recently, MXene, are the main representatives of the family of two-dimensional (2D) materials and are widely studied as multimodal nanoplatforms for cancer diagnostics and treatment, in particular leveraging their potentialities as photodynamic therapeutic agents. Indeed, due to their irreplaceable physicochemical properties, they are virtuous allies for photodynamic therapy (PDT) in combination with bioimaging, photothermal therapy, as well as drug and gene delivery. In this review, the rapidly progressing literature related to the use of these promising 2D materials for cancer theranostics is described in detail, highlighting all their possible future advances in PDT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available